Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir], which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir. Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior. It is grouped under the following drug class(es): HIV-1 Integrase Inhibitors. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include cabotegravirum and Apretude. Its PubChem CID is 54713659.